Portal Hypertension
On this page
Direct answer
A hepatic venous pressure gradient of 10 mmHg or more — clinically significant portal hypertension — marks the point at which varices form and decompensation becomes possible, and it anchors every management decision from beta-blockade to transplant listing. Management begins with locating the block: pre-hepatic (portal vein thrombosis, the dominant cause in Indian children with extrahepatic portal vein obstruction), intrahepatic sinusoidal (cirrhosis), pre-sinusoidal (schistosomiasis, non-cirrhotic portal hypertension) or post-hepatic (Budd-Chiari syndrome, right heart failure). Cirrhotic portal hypertension is managed across the Baveno VII stages — compensated without significant portal hypertension, compensated with CSPH, and decompensated — with carvedilol preventing decompensation in the middle stage, and TIPS or transplant reserved for refractory bleeding, refractory ascites or hepatorenal syndrome in selected patients.
What you must remember
- Pressure ladder: normal HVPG 3–5 mmHg; 10 mmHg or more predicts varices and clinical decompensation; 12 mmHg or more is the threshold above which variceal rupture occurs; gradients above roughly 16–20 mmHg carry the worst outcomes in bleeding and acute illness.
- Site-of-block discriminations: schistosomiasis and non-cirrhotic portal hypertension raise splenic-portal pressure with a normal HVPG, because the sinusoids are free; Budd-Chiari presents with painful hepatomegaly, ascites and hepatic-vein occlusion on Doppler; portal vein thrombosis presents with varices and hypersplenism with preserved liver function.
- Non-cirrhotic portal hypertension in India: EHPVO and non-cirrhotic portal fibrosis together account for a substantial share of paediatric and young-adult variceal disease; liver chemistry and synthetic function are typically normal, and management is largely endoscopic.
- HVPG measurement: the gold standard, via a transjugular balloon-occluded hepatic vein catheter; a treatment response is a gradient fall of at least 10 per cent or to 12 mmHg or below.
- Carvedilol in compensated CSPH: 12.5 mg daily reduces the probability of first decompensation (bleeding, ascites, encephalopathy) and is the only therapy with that proven outcome benefit in the compensated stage.
- TIPS physiology: a side-to-side portosystemic shunt decompressing the portal system; indications include refractory variceal bleeding and refractory ascites in selected patients, plus early/pre-emptive use after acute bleeding in Child B/C disease.
- TIPS contraindications: severe congestive heart failure, severe tricuspid regurgitation, severe pulmonary hypertension, uncontrolled systemic infection, unrelieved biliary obstruction, and extensive polycystic liver disease; Child C 14 or above predicts futility.
- Post-TIPS discipline: watch for hepatic encephalopathy (commonest new problem), contrast for stent patency, and Doppler surveillance for dysfunction.
Reasoning through three different blocks
Consider three Indian outpatients with varices. A nine-year-old with anaemia and splenomegaly but normal synthetic function has extrahepatic portal vein thrombosis on Doppler — endoscopic eradication of varices and management of hypersplenism, with anticoagulation reserved for extension or thrombophilia; the liver itself is healthy, so no beta-blocker logic or transplant applies. A 50-year-old with hepatitis C cirrhosis, stiffness 28 kPa and oesophageal varices sits in the compensated-CSPH stage: carvedilol now, because preventing first decompensation is the only modifiable outcome. A 34-year-old woman with acute abdominal pain, tense ascites and hepatomegaly has hepatic-vein thrombosis — evaluate for a myeloproliferative disorder and antiphospholipid syndrome, anticoagulate, and consider angioplasty or TIPS for the dominant obstruction. The single number each case turns on is where the pressure is blocked, which is why examiners pair a "site of obstruction" question with an "HVPG result" question in the same stem.
Where candidates lose marks
The recurring slip is applying cirrhotic algorithms to non-cirrhotic disease — offering TIPS or transplant to an EHPVO child whose liver is architecturally normal. The second is forgetting that HVPG measures sinusoidal and post-sinusoidal pressure only; in pre-sinusoidal disease it underestimates portal pressure, and a "normal HVPG with varices" should prompt a schistosomiasis or NCPH workup rather than a repeat procedure. Finally, TIPS questions are decided by the contraindications and the futility scores (Child C beyond 13, high bilirubin, poor cardiac function) — the stem always hides one disqualifier.
Frequently asked questions
What HVPG value defines clinically significant portal hypertension?
10 mmHg or above; this threshold predicts formation of varices, first clinical decompensation and benefit from beta-blockade.
Why can HVPG be normal despite evident portal hypertension?
In pre-sinusoidal disease — schistosomiasis, non-cirrhotic portal fibrosis, and early extrahepatic portal vein obstruction — the sinusoidal bed is uninvolved, so the wedged hepatic venous pressure does not reflect the elevated splenic-portal pressure.
What is the commonest cause of portal hypertension in Indian children?
Extrahepatic portal vein obstruction; variceal bleeding occurs with preserved hepatic synthetic function, and management is primarily endoscopic.
When is carvedilol indicated in compensated cirrhosis?
When non-invasive testing suggests clinically significant portal hypertension — liver stiffness above 25 kPa — to prevent the first episode of clinical decompensation.
List the major contraindications to TIPS.
Congestive heart failure and severe tricuspid regurgitation, severe pulmonary hypertension, uncontrolled sepsis, unrelieved biliary obstruction, polycystic liver disease, and very advanced Child C disease in which the procedure is futile.